India’s Pharmaceuticals in Global Healthcare

Introduction:

The pharmaceutical industry is a critical driver of both public health outcomes and economic growth. India has emerged as a major pharmaceutical producer, combining technological advancement with socially significant contributions to healthcare.

India in the Global Pharmaceuticals Market:

Known as the “Pharmacy of the World,” India is preferred globally for its affordable pricing and assured quality.

• • Global Standing: India ranks 3rd globally by volume and 11th by value, with over 3,000 companies and 10,500 manufacturing units.
  • Market Growth: The domestic market is valued at USD 60 billion and is projected to reach USD 130 billion by 2030.
  • Generic Powerhouse: India is the largest global supplier of generic medicines, accounting for 20% of global supply across 60 therapeutic categories.
  • USFDA Approvals: India hosts the highest number of USFDA-approved manufacturing plants outside the United States, reinforcing international trust.

Global Reach and Investment:

India’s export-driven growth is underpinned by its critical role in global health networks.

• • Vaccine Leadership: Indian manufacturers meet 40–70% of global demand for DPT and BCG vaccines and account for 90% of the WHO’s measles vaccine demand.
  • Export Value: In 2024–25, pharmaceutical exports stood at USD 30.5 billion, reaching 191 countries. Approximately 50% of these exports are directed to highly regulated markets in the U.S. and Europe.
  • Medical Devices: Exports in this segment grew from USD 2.5 billion in 2020–21 to USD 4.1 billion in 2024–25.
  • Foreign Direct Investment (FDI): The sector is a top-10 industry for FDI, with flows reaching ₹13,193 crore in FY26 (up to September).

Strengthening Exports through Trade Agreements:

Recent trade agreements are designed to deepen India’s integration into global healthcare value chains.

Government Interventions and Production Linked Incentive (PLI) Schemes:

PLI schemes are the cornerstone of efforts to reduce import dependence and boost domestic manufacturing.

1. PLI for Pharmaceuticals

• • Focus: High-value biopharmaceuticals, complex generics, and autoimmune drugs.
  • Sales & Exports: Total sales reached ₹3,16,797 crore (up to September 2025), with exports accounting for ₹2,03,730 crore.
  • Employment: Approximately 97,000 persons have been employed under this scheme.

2. PLI for Bulk Drugs (APIs/KSMs/DIs)

• • Established Capacity: Manufacturing capacity of 55,100 metric tonnes per year has been created for 26 critical inputs.
  • Import Avoidance: PLI schemes have already helped avoid imports worth ₹3,591 crore.

3. PLI for Medical Devices

• • Performance: Attracted an actual investment of ₹1,093.69 crore with cumulative sales of ₹12,344.37 crore.

Infrastructure and Innovation Initiatives:

To further strengthen the ecosystem, the government is investing in specialized parks and research.

• • Bulk Drug Parks: Three parks are under development in Andhra Pradesh, Gujarat, and Himachal Pradesh with a total project cost exceeding ₹6,306.68 crore.
  • Medical Devices Parks: Three parks are being established in Uttar Pradesh, Madhya Pradesh, and Tamil Nadu.
  • Biopharma SHAKTI: Launched in the Union Budget 2026–27 with a ₹10,000 crore outlay to build an ecosystem for domestic production of biologics and biosimilars. It includes establishing 3 new NIPERs and creating 1,000 accredited clinical trial sites.
  • Affordability (PMBJP): Over 18,646 Jan Aushadhi Kendras are operational as of February 2026, providing quality generic medicines and sanitary napkins at highly subsidized rates.

Governance and Regulation:

India’s pharmaceutical system is anchored by a robust regulatory framework.

• • CDSCO: The national authority overseeing new drug approvals and clinical trials to ensure safety and quality.
  • NPPA: Responsible for fixing and revising drug prices to ensure the availability of essential medicines.
  • IPC: Manages the Indian Pharmacopoeia, a compendium of drug standards recognized in 19 countries.

Challenges:

• • Reliance on Raw Materials: Despite PLI successes, a significant portion of Key Starting Materials (KSMs) and Drug Intermediates still rely on imports from a single dominant source, posing a supply chain risk.
  • R&D Intensity: While India leads in generic volume, transitioning to innovation-led growth (new chemical entities) requires substantially higher R&D investment compared to the current industry average.
  • Regulatory Compliance: Maintaining the highest quality standards across 10,500 units is a massive undertaking; any compliance failure at a major unit can impact the “India Brand” globally.
  • Pricing Pressures: Global competition in the generic market and strict domestic price controls by the NPPA can limit the profit margins available for reinvestment into high-end research.

Way Forward:

• • NIPER Upgradation: Strengthening the institutional network by establishing 3 new NIPERs and upgrading 7 existing ones to create a specialized workforce.
  • Clinical Trial Expansion: Developing a network of over 1,000 accredited clinical trial sites to support the discovery of new therapies.
  • Market Diversification: Strategically expanding exports to emerging destinations like Nigeria, Mexico, Brazil, and Saudi Arabia to mitigate regional tariff risks.
  • Generic-to-Innovation Pivot: Leveraging the PRIP scheme to move beyond generic manufacturing toward precision medicine and novel medical devices.

Conclusion:

Through targeted schemes like PLI and Biopharma SHAKTI, along with expanding global trade linkages, India is positioned on a forward-looking trajectory that supports long-term healthcare resilience and economic growth.

Spread the Word

The post India’s Pharmaceuticals in Global Healthcare appeared first on Lukmaan IAS.